Global Intravenous Immunoglobulin Market – Industry Trends and Forecast to 2030

Intravenous Immunoglobulin Market Analysis and Size

Immunoglobulin are manufactured from a huge pool of human plasma that is collected from at least 100 donors or more. The intramuscular route of administration is a conventional method and is not preferred currently, as it is painful. Intravenous immunoglobulin has developed as a boon in the last few years for patients with compromised immune systems. The increasing burden of target diseases such as primary immunodeficiency diseases is projected to boost the growth of the market.

Data Bridge Market Research analyses a growth rate in the intravenous immunoglobulin market in the forecast period 2023-2030. The expected CAGR of intravenous immunoglobulin market is tend to be around 7.80% in the mentioned forecast period. The market was valued at USD 11.97 million in 2022, and it would grow upto USD 21.83 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Intravenous Immunoglobulin Market Scope and Segmentation

Market Definition

Immunoglobulin is the product breakdown of blood plasma that contains antibody. Immunoglobulin is a blood product which is generally administered through intravenous route. It consists of polyvalent IgG antibodies extracted from blood donors' plasma. Many patients are suffering from disorders such Wiskott Aldrich Syndrome, X-linked agammaglobulinemia who are unable to produce enough antibodies. Thus they benefit from intravenous immunoglobulin to maintain the sufficient level of antibodies in the body.

Global Intravenous Immunoglobulin Market Dynamics

Drivers

• Growing Incidences of Primary Immune Deficiencies (PIDs)

As per W.H.O, at present, there are more than 50 different Primary Immune Deficiencies (PIDs) such as specific antibody deficiency and X-lined hypo-gamma-globulinemia. This deficiences include 176 different types of rare hereditary disorders. As per the U.S. National Library of Medicine and National Institute of Health, around 6 million patients are suffering from PID globally. Increasing occurrences of these diseases are anticipated to boost the demand for immunoglobulin therapies during the forecast period.

• Growing Demand For Hospitals For These Patients

The hospitals segment dominated the market due to increase in the number of patients opting for hospital treatment rather than standalone clinics. Furthermore, patients receiving IVIG infusions at home have improved the quality of life, as they get more comfortable in the daily activities. For instance, IVIG infusions at home care have minimized the scheduling clashes for multiple patients at a time.

Opportunities

• Increasing Healthcare Expenditure For Immunoglobulins

There has been increasing funding for several immunoglobulins that are helping to expand the market's growth. For instance, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the phase III trial, known as Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. The antibody solution which was tested in the ITAC trial is anti-coronavirus hyperimmune intravenous immunoglobulin or hIVIG.  

• Increasing Strategic Partnerships and Acquisitions between Organizations

Several market players are adopting numerous strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a huge share by growing their market penetration. For instance, on 25 April 2022, Grifols S.A purchased Biotest, which is a significant and transformative deal that will boost growth and innovation. This deal will allow to accelerate and extend its product range, increase patient access to plasma medicines, operate the biggest private European network of plasma facilities, and increase revenue growth and margin development.

Restraints/Challenges

• High Cost of Treatment

The cost for diagnosis and treatment of demyelinating disease is very high. The increasing cost of IVIG therapy is estimated to be a major barrier to market expansion. Immunoglobulin infusions are typically given once every 3 to 4 weeks, and the therapy is ongoing about 12-16 sessions annually. The projected cost of IVIG is USD 73.89 per gram, with a total cost of USD 10,000, depending on the severity of the patient condition.

This intravenous immunoglobulin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the intravenous immunoglobulin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Intravenous Immunoglobulin Market

COVID-19 has caused significant issues for patients with mental and neurological disorders because of their increased susceptibility to infection. MIS-C (multi-system inflammatory syndrome) has been witnessed in several patients, especially among the younger population. Several medical professionals have been estimating the efficacy of IVIG injection for COVID-19 patients. For instance, in April 2021, Grifols, S.A. which is a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients, which is projected to boost the market growth during the forecast period.

Recent Development:

• In August 2021, Emergent BioSolutions, Inc., which is a multinational specialty biopharmaceutical company based in the U.S., stated the initiation of phase III clinical trial to assess its investigational SARS-CoV-2 Immune Globulin Intravenous (COVID-HIG) plasma-derived therapy as a capable outpatient treatment for patients with COVID-19 who are at higher risk of progression to severe disease. Therefore, the factors mentioned above are estimated to boost the growth of the global intravenous immunoglobulin market during the forecast period.

Global Intravenous Immunoglobulin Market Scope

The intravenous immunoglobulin market is segmented on the basis of application, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Hypogammaglobulinemia
• CIDP
• Congential AIDS

Route of Administration

• Intravenous
• Subcutaneous

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Intravenous Immunoglobulin Market Regional Analysis/Insights

The intravenous immunoglobulin market is analyzed and market size insights and trends are provided by application, route of administration,end-user, distribution channel as referenced above.

The major countries covered in the intravenous immunoglobulin market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.

Asia-Pacific is dominating the market due to the growing awareness and potential opportunities for adopting immunoglobulin-based therapies for treating patients with primary immune deficiencies, along with a growing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Intravenous Immunoglobulin Market Share Analysis

The intravenous immunoglobulin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to intravenous immunoglobulin market.

Key players operating in the intravenous immunoglobulin market include:

• Baxter (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Biotest AG (Germany)
• Top Bio Group Co., Ltd.(China)
• CSL Limited (Australia)
• Octapharma AG (Switzerland)
• Grifols, S.A (Spain)
• Kedrion S.p.A (Italy)

SKU-57226